MedTrace Logo

Efficacy of Autologous Conditioned Serum in Temporomandibular Joint Disorder

NCT06839326 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2026-03-17

No results posted yet for this study

Summary

Temporomandibular joint (TMJ) disorders are health conditions that can occur at any age and are recognized as the most common cause of chronic pain, affecting 5-12% of the population. Pain in the TMJ region can lead to limitations in mouth opening and lateral movements of the mandible.

In cases where conservative treatments are insufficient for TMJ disorders and osteoarthritis, symptoms can be alleviated through arthrocentesis, a minimally invasive procedure with a low risk of complications, or through various intra-articular injection applications following arthrocentesis.

This study aims to compare the clinical efficacy of intra-articular applications of platelet-rich plasma (PRP) and autologous conditioned serum (ACS), both derived from the patient's own blood, in order to evaluate their impact on treatment outcomes and their potential role in enhancing patient care in routine clinical practice."

Conditions

  • Temporomandibular Joint Osteoarthritis

Interventions

BIOLOGICAL

Autologous Conditioned Serum, Genesis Biyomedikal, Sanakin®-Acrs produce

Arthrocentesis and 1ml ACS injection will be performed twice in total, two weeks apart.

BIOLOGICAL

Platelet Rich Plasma

Arthrocentesis and 1ml PRP injection will be performed twice in total, two weeks apart.

OTHER

Control Group/ Only Arthrocentesis

Arthrocentesis will be performed twice in total, two weeks apart.

Sponsors & Collaborators

  • Batman University

    lead OTHER

Principal Investigators

  • Rojdan F GÜNEŞ UYSAL, PhD · Batman University

  • İbrahim UYSAL, PhD · Dicle University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-06-01
Completion
2025-08-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06839326 on ClinicalTrials.gov